drugset / Trial / NCT05784701
Trivalent Salmonella Conjugate Vaccine (TSCV)
Phase 2
Active not recruiting
800 enrolled
University of Maryland, Baltimore
Bharat Biotech International Limited · collabWellcome Trust · collab
RandomizedParallel-groupTriple-blindOther
Summary
This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.
Timeline
- Start
- 2023-04-05
- Primary completion
- 2027-01-05
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trivalent Salmonella Conjugate Vaccine | Vaccine | — | Other |
| Comparator | Typbar-TCV | Vaccine | — | — |
Indications
No indication recorded.